Stockscreener 앱 받기
1.10
1.85%
0.02
시간 외 거래:
1.10
전일 마감가:
$1.08
열려 있는:
$1.09
하루 거래량:
200.35K
Relative Volume:
0.53
시가총액:
$58.66M
수익:
-
순이익/손실:
$-78.34M
주가수익비율:
-0.7423
EPS:
-1.4819
순현금흐름:
$-75.02M
1주 성능:
+3.77%
1개월 성능:
-14.73%
6개월 성능:
-2.65%
1년 성능:
+0.92%
1일 변동 폭
$1.06
$1.14
1주일 범위
$1.035
$1.14
52주 변동 폭
$0.9642
$1.88
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
명칭
Pmv Pharmaceuticals Inc
전화
(609) 642-6670
주소
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.10 | 56.53M | 0 | -78.34M | -75.02M | -1.4819 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-05-13 | 개시 | Craig Hallum | Buy |
| 2024-04-12 | 개시 | Jefferies | Buy |
| 2023-12-27 | 개시 | Ladenburg Thalmann | Buy |
| 2022-03-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-09-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-08-19 | 개시 | Oppenheimer | Perform |
| 2021-08-02 | 개시 | Guggenheim | Buy |
| 2021-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-10-20 | 개시 | Cowen | Outperform |
| 2020-10-20 | 개시 | Evercore ISI | Outperform |
| 2020-10-20 | 개시 | Goldman | Neutral |
모두보기
Pmv Pharmaceuticals Inc 주식(PMVP)의 최신 뉴스
PMV Pharmaceuticals Stock (US7301281085): Quiet session puts fundamentals and balance sheet in focus - AD HOC NEWS
PMV Pharmaceuticals (PMVP) loses 26% in 4 weeks, here's why a trend reversal may be around the corner - MSN
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
PMV Pharmaceuticals Slips Slightly as Shares Approach Critical SupportCounter Trend Trade - newsline.com
PMV Pharmaceuticals (PMVP) grants director 42,000 options at $1.19 - Stock Titan
PMV Pharmaceuticals (PMVP) director receives 42,000 stock options at $1.1900 - Stock Titan
PMV Pharmaceuticals (PMVP) director gifts 84K stock options to trust - Stock Titan
PMV Pharmaceuticals (PMVP) director awarded 42,000 stock options at $1.19 - Stock Titan
Director at PMV Pharmaceuticals (PMVP) granted 42,000 options at $1.19 - Stock Titan
PMV Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results - Minichart
PMV Pharmaceuticals Shareholders Back Directors and Governance Matters - TipRanks
Shareholders back PMV Pharmaceuticals (NASDAQ: PMVP) board, pay plans - Stock Titan
PMVP: Directors elected, compensation and auditor ratified, with no stockholder questions raised - TradingView
PMV Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
PMV Pharmaceuticals Q1 2026 Earnings: EPS Beat Narrows Losses Amid Pre-Revenue Pipeline ProgressEarnings Season Outlook - newsline.com
PMVP Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseNext Quarter Guidance - newsline.com
PMV Pharmaceuticals Advances Cancer Study Amid Adjusted Financial Targets - asatunews.co.id
PMV Pharmaceuticals Advances Cancer Drug Development Amid Financial Adjustments - sekbernews.id
Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity - Insider Monkey
5 Popular Penny Stocks on Robinhood to Watch in 2026 - Insider Monkey
PMVP Q1 2026 Earnings: Narrower Loss Slightly Beats Estimates as Development AdvancesRevenue Miss Report - The Legal Advocate
PMV Pharmaceuticals’ Phase 2 Clinical Trial Progresses; Reports $5 Million in First-Quarter Revenue - geneonline.com
PMV Pharmaceuticals (PMVP) Slips to $1.26 as Cautious Trading Puts Support to the TestCalendar Spread Trade - Newser
PMV Pharmaceuticals, Inc.Common Stock (Nasdaq:PMVP) Stock Quote - FinancialContent
PMV Pharmaceuticals (PMVP) Q1 2026 Earnings Surprise: EPS $-0.34, Up SignificantProfit Cycle Analysis - The Legal Advocate
Number of shareholders of PMV Pharmaceuticals, Inc. – NASDAQ:PMVP - TradingView
Euclidean Capital reports 2.6M shares in PMVP (PMVP) - Stock Titan
PMV Pharmaceuticals (PMVP) Q1 2026 Earnings: Why the Beat MattersShared Trade Ideas - newser.com
PMV Pharmaceuticals (PMVP) price target decreased by 37.50% to 4.84 - MSN
PMVP Maintains Outperform Rating by Oppenheimer -- Price Target Lowered to $5.00 - GuruFocus
Oppenheimer Maintains PMV Pharmaceuticals(PMVP.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
12 Health Care Stocks Moving In Wednesday's After-Market SessionAquestive Therapeutics (NASDAQ:AQST) - Benzinga
Oppenheimer Adjusts Price Target on PMV Pharmaceuticals to $5 From $6, Maintains Outperform Rating - marketscreener.com
TradingKey - TradingKey
PMVP Advances PYNNACLE Study and NDA Submission Timeline - GuruFocus
PMV Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
PMV Pharmaceuticals stock (US7301281085): Q1 2026 results and rezatapopt orphan drug nod - AD HOC NEWS
PMV Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
PMV Pharmaceuticals 1Q Loss/Shr 34c >PMVP - Moomoo
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
PMV Pharmaceuticals' Q1 net loss widens - TradingView
PMV Pharmaceuticals 1Q 2026: Net loss $18M, EPS $(0.34) — 10-Q Summary - TradingView
PMV Pharmaceuticals 1Q Loss $18M >PMVP - Moomoo
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
8-K: PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlightsmoomoo - Moomoo
PMV Pharmaceuticals (NASDAQ: PMVP) reports Q1 2026 loss and details rezatapopt progress - Stock Titan
PMV Pharmaceuticals (NASDAQ: PMVP) Q1 2026 loss, strong rezatapopt data and orphan status - Stock Titan
PMV Pharmaceuticals (PMVP) Eps Diluted (TTM) - Zacks Investment Research
PMV Pharmaceuticals Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Sio Capital (PMVP) discloses 3,076,580 shares, 5.77% stake in PMV Pharmaceuticals - Stock Titan
PMV Pharmaceuticals (PMVP) to Release Earnings on Friday - MarketBeat
Pmv Pharmaceuticals Inc (PMVP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pmv Pharmaceuticals Inc 주식 (PMVP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Oct 23 '25 |
Sale |
1.52 |
1,000,000 |
1,520,000 |
4,975,291 |
2.60%
0.94%
자본화:
|
볼륨(24시간):